Unbound MEDLINE

Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.

Abstract

Antipsychotics have proven efficacy for treating patients with early-onset schizophrenia, and aripiprazole, olanzapine, quetiapine, and risperidone have FDA approval for treating adolescents aged 13 to 17 years. Children and adolescents appear to have a higher risk than adults for experiencing adverse events such as extrapyramidal symptoms, prolactin elevation, weight gain, and metabolic effects when taking antipsychotic medications. Pediatric studies indicate that adverse effect profiles differ among commonly used antipsychotics. Clinicians should consider the differing adverse effect profiles when choosing medications for young patients.

Links

  • Publisher Full Text

    • Authors

    Correll CU

    Institution

    From the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA.

    Source

    The Journal of clinical psychiatry 72:8 2011 Aug pg e26

    MeSH

    Adolescent
    Age Factors
    Antipsychotic Agents
    Child
    Humans
    Risk
    Schizophrenia

    Pub Type(s)

    Interactive Tutorial

    Language

    eng

    PubMed ID

    21899814